GlassScriptPhysician profile
Huy K Hoang
NPI 1962461020
$3,585.66
in general payments reported to CMS, 2019-2025
18 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $120 · 2021: $494 · 2022: $840 · 2023: $606 · 2024: $897 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $479.78 | 2019-2024 | Otezla, Tepezza |
| Novo Nordisk INC | $365.65 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $356.32 | 2020-2022 | |
| Abbvie INC. | $348.31 | 2022-2025 | Creon |
| Astrazeneca Pharmaceuticals LP | $249.89 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $243.90 | 2023-2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.55 | 2021-2023 | Trulance |
| Boston Scientific Corporation | $147.62 | 2025 | Farapulse |
| Madrigal Pharmaceuticals | $144.17 | 2024 | Rezdiffra |
| Agios Pharmaceuticals, INC. | $135.71 | 2024 | Pyrukynd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Nestle Healthcare Nutrition INC. | $124.98 | 2021 | |
| Phathom Pharmaceuticals, INC. | $123.86 | 2024 | Voquezna |
| Mylan Specialty L.P. | $123.07 | 2022 | |
| Horizon Therapeutics Plc | $121.63 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $120.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $119.65 | 2023 | Dupixent |
| Glaxosmithkline, LLC. | $58.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huy Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.